Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients.

Summary: Idelalisib, a reversible inhibitor of PI3Kδ (phosphoinositide‐3 kinase delta), showed remarkable activity in the phase II DELTA trial, leading to its approval by the European Medicines Agency (EMA) in patients with relapsed/refractory (R/R) follicular lymphoma (FL). However, real‐life data on idelalisib are scarce. We treated 55 double‐refractory FL patients with idelalisib in a real‐life setting. With a median exposure to idelalisib of 10 months (range 1–43), overall response rate was 73%, the highest ever reported. Non‐haematological toxicities were mild and manageable. At 12 months, 80% of patients were alive, and 72% disease‐free. The efficacy and safety of idelalisib was confirmed in a real‐life setting. [ABSTRACT FROM AUTHOR]